Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02555657

Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)

Metastatic Triple Negative Breast Cancer Clinical Trial

Official title:
A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab Versus Single Agent Chemotherapy Per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC) - (KEYNOTE-119)

Clinical Trial Summary

In this study, participants with metastatic triple negative breast cancer (mTNBC) will be randomly assigned to receive either single agent pembrolizumab or single agent chemotherapy chosen by the treating physician (Treatment of Physician's Choice, TPC) in accordance with local regulations and guidelines, consisting of either capecitabine, eribulin, gemcitabine, or vinorelbine. The primary study hypothesis is that pembrolizumab extends overall survival compared to TPC.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02555657
Study type Interventional
Source Merck Sharp & Dohme Corp.
Contact
Status Completed
Phase Phase 3
Start date October 13, 2015
Completion date November 10, 2020
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02158507 - Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer N/A
Completed NCT02834403 - L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients Phase 1/Phase 2
Completed NCT03121352 - Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer Phase 2
Active, not recruiting NCT03330847 - To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. Phase 2
Completed NCT03256344 - Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases Phase 1
Recruiting NCT04739670 - Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer Phase 2
Withdrawn NCT01936961 - Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors N/A
Completed NCT01238952 - Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer Phase 1
Completed NCT03577743 - Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer Phase 2
Completed NCT03411161 - S 81694 Plus Paclitaxel in Metastatic Breast Cancer Phase 1/Phase 2
Withdrawn NCT04149444 - A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer Phase 2
Withdrawn NCT05008510 - P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC . Phase 2
Completed NCT04111510 - Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer Phase 2
Terminated NCT03055312 - Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer Phase 3
Recruiting NCT03709446 - Leflunomide in Previously Treated Metastatic Triple Negative Cancers Phase 1/Phase 2